Detalhe da pesquisa
1.
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Am J Respir Crit Care Med
; 204(11): 1295-1305, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469706
2.
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.
Clin Infect Dis
; 69(10): 1812-1816, 2019 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31056660
3.
Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
Eur Respir J
; 63(6)2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843940
4.
Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116-121].
J Pediatr
; 255: 265, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36653281
5.
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
Curr Opin Pulm Med
; 23(6): 530-535, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28708817
6.
Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens.
J Clin Microbiol
; 54(3): 613-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26699705
7.
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.
J Pediatr
; 169: 116-21.e2, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26388208
8.
Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes.
Eur Respir J
; 55(4)2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32245773
9.
Decade-long bacterial community dynamics in cystic fibrosis airways.
Proc Natl Acad Sci U S A
; 109(15): 5809-14, 2012 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451929
10.
Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.
J Pediatr
; 165(6): 1091-1097.e2, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25134852
11.
Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative.
J Cyst Fibros
; 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480113
12.
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Ann Am Thorac Soc
; 21(4): 595-603, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963297
13.
The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?
Ann Intern Med
; 166(8): 599-600, 2017 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28289748
14.
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
J Cyst Fibros
; 22(5): 864-867, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803635
15.
Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.
J Cyst Fibros
; 22(5): 875-879, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407341
16.
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
Ann Am Thorac Soc
; 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096105
17.
The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.
J Pediatric Infect Dis Soc
; 11(Supplement_2): S40-S45, 2022 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36069900
18.
Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
J Cyst Fibros
; 21(5): 766-768, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667975
19.
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.
J Cyst Fibros
; 21(4): 594-599, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35300932
20.
Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.
Pediatr Pulmonol
; 56(5): 823-836, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434406